Abstract
Liposomal bupivacaine has been the topic of intense academic debate over the past years culminating in an industry-initiated libel lawsuit against the American Society of Anesthesiologists and various other defendants. In this Daring Discourse, we first aim to provide a general overview of main themes in the ongoing controversy: (1) between-study heterogeneity, (2) the high number of negative high-quality reviews and meta-analyses, (3) publication bias in the context of an active role of industry and (4) difference between statistical and clinical significance. We then discuss the contents of the lawsuit, its potential implications and what the recent resolution of this lawsuit means for the future of research and the academic discourse on liposomal bupivacaine.
Subject
Anesthesiology and Pain Medicine,General Medicine
Reference23 articles.
1. Clinical effectiveness of liposomal bupivacaine administered by infiltration or peripheral nerve block to treat postoperative pain;Ilfeld;Anesthesiology,2021
2. The mornings after—periarticular liposomal bupivacaine infiltration does not improve analgesic outcomes beyond 24 hours following total knee arthroplasty: a systematic review and meta-analysis
3. Efficacy of liposomal bupivacaine in shoulder surgery: a systematic review and meta-analysis;Kolade;J Shoulder Elbow Surg,2019
4. Perineural liposomal bupivacaine is not superior to nonliposomal bupivacaine for peripheral nerve block analgesia;Hussain;Anesthesiology,2021
5. United States District Court, District of New Jersey . Civil Action No. 2:21 Civ. 9264. Complaint and demand for jury trial. Pacira Biosciences, Inc. v. American Society of Anesthesiologists, Inc., Evan D. Kharasch, Nasir Hussain, Richard Brull, Brendan Sheehy, Michael K. Essandoh, David L. Stahl, Tristan E. Weaver, Faraj W. Abdallah, Brian M. Ilfeld, James C. Eisenach, Rodney A. Gabriel, and Mary Ellen McCann. Available: https://ecf.njd.uscourts.gov/doc1/119117242940 [Accessed 28 Mar 2023].